Asthma
Conditions
Sponsors
Novartis Pharma K.K.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: * Written informed consent must be obtained before any assessment is performed. * Male and female adult patient >= 18 years old. * Patients with a diagnosis of persistent asthma (GINA 2016) for a period of at least 1 year prior to Visit 1. * Patients who have used medium or high dose ICS plus at least 1 controller for asthma for at least 3 months and at stable dose and regimen for at least 4 weeks prior to Visit 1. * Patients must have ACQ-7 score >= 1.5 at Visits 2 and qualify for treatment with high dose ICS/LABA. * Pre-bronchodilator FEV1 of >= 50% and == 12% and 200 mL within 15 to 30 minutes after administration of 400 microgram of salbutamol at Visit 2. Spacer devices are permitted during reversibility testing only. The Investigator or delegate may decide whether or not to use a spacer for the reversibility testing. - If reversibility is not proven at Visit 2, patients may be permitted to enter the study with historical evidence of reversibility that was performed within 5 years prior to Visit 1. - Alternatively, patients may be permitted to enter the study with a historical positive bronchoprovocation test (defined as a provoked fall in FEV1 of 20% by bronchoconstriction agent e.g., methacholine, histamine) or equivalent test (e.g., astography) that was performed within 5 years prior to Visit 1. - If reversibility is not proven at Visit 2 and historical data is not available, reversibility should be repeated once in an ad-hoc visit scheduled as close as possible from the first attempt (but not on the same day).
Exclusion criteria
Exclusion criteria: * Patients who have had an asthma attack/exacerbation requiring systemic steroids or hospitalization or emergency room visit within 6 weeks of Visit 1. * Patients who have ever required intubation for a severe asthma attack/exacerbation. * Patients who have a clinical condition which is likely to be worsened by ICS administration (e.g. glaucoma, cataract and fragility fractures) who are according to investigator's medical judgment at risk participating in the study. * Patients who have had a respiratory tract infection or asthma worsening as determined by investigator within 4 weeks prior to Visit 1 or between Visit 1 and Visit 99. Patients may be re-screened 4 weeks after recovery from their respiratory tract infection or asthma worsening. * Patients with a history of chronic lung diseases other than asthma, including (but not limited to) chronic obstructive pulmonary disease, sarcoidosis, interstitial lung disease, cystic fibrosis, clinically significant bronchiectasis and active tuberculosis. * Patients with severe narcolepsy and/or insomnia. * Pregnant or nursing (lactating) women. * Women of child-bearing potential unless they are using highly effective methods of contraception during dosing and for 30 days after stopping of investigational medication. Other protocol defined inclusion/exclusion criteria may apply.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| safety The number of patients who reported treatment emergent adverse events during the 52 weeks of the study [ Time Frame: 52 weeks ] The number of participants who experienced treatment emergent adverse events over 52 weeks of treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| efficacy Trough FEV1 [ Time Frame: 26 and 52 weeks ] FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing. efficacy PEF [ Time Frame: 52 weeks ] Measured in the morning and evening. PEF is the peak expiratory flow, the maximum speed of expiration. efficacy ACQ-7 [ Time Frame: 26 and 52 weeks ] ACQ is the Asthma Control Questionnaire (scoring 5 symptoms, FEV1 entered by the investigator and the rescue medication use entered by the patient) validated to evaluate different levels of asthma control. safety Rescue medication [ Time Frame: 26 and 52 weeks ] The mean daily number of puffs of rescue medication use over the first 26 weeks and over the 52 weeks of treatment and the mean change from baseline are summarized. | — |
Countries
Japan
Outcome results
None listed